PL3426237T3 - Sposób leczenia zaniku mózgu - Google Patents

Sposób leczenia zaniku mózgu

Info

Publication number
PL3426237T3
PL3426237T3 PL17716067.8T PL17716067T PL3426237T3 PL 3426237 T3 PL3426237 T3 PL 3426237T3 PL 17716067 T PL17716067 T PL 17716067T PL 3426237 T3 PL3426237 T3 PL 3426237T3
Authority
PL
Poland
Prior art keywords
treating brain
brain atrophy
atrophy
treating
brain
Prior art date
Application number
PL17716067.8T
Other languages
English (en)
Inventor
Mattheus Cornelis De Wilde
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Publication of PL3426237T3 publication Critical patent/PL3426237T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17716067.8T 2016-03-08 2017-03-08 Sposób leczenia zaniku mózgu PL3426237T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2016/050160 WO2017155386A1 (en) 2016-03-08 2016-03-08 Method for treating brain atrophy
PCT/NL2017/050141 WO2017155396A1 (en) 2016-03-08 2017-03-08 Method for treating brain atrophy

Publications (1)

Publication Number Publication Date
PL3426237T3 true PL3426237T3 (pl) 2024-04-08

Family

ID=55863158

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17716067.8T PL3426237T3 (pl) 2016-03-08 2017-03-08 Sposób leczenia zaniku mózgu

Country Status (13)

Country Link
US (1) US20190076375A1 (pl)
EP (2) EP3426237B1 (pl)
JP (1) JP6980678B2 (pl)
CN (1) CN109069447A (pl)
AU (1) AU2017231577B2 (pl)
BR (1) BR112018068110A2 (pl)
ES (1) ES2962361T3 (pl)
FI (1) FI3426237T3 (pl)
HR (1) HRP20231115T1 (pl)
PL (1) PL3426237T3 (pl)
PT (1) PT3426237T (pl)
SI (1) SI3426237T1 (pl)
WO (2) WO2017155386A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE072655T2 (hu) * 2018-11-30 2025-12-28 Evonik Operations Gmbh Foszfolipidek és zsírsav-sók diszperzióját tartalmazó készítmény
JP7506473B2 (ja) * 2019-12-20 2024-06-26 ポッカサッポロフード&ビバレッジ株式会社 アミロイドβ蓄積抑制剤
WO2021167876A1 (en) * 2020-02-21 2021-08-26 Hi Llc Methods and systems for initiating and conducting a customized computer-enabled brain research study
AU2022345465A1 (en) 2021-09-17 2024-03-21 N.V. Nutricia Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4880190B2 (ja) * 2001-04-30 2012-02-22 トロムスドルフ ゲーエムベーハー ウント コンパニー カーゲー アルツナイミッテル 医薬として活性なウリジンエステル
PT1390378E (pt) * 2001-04-30 2009-07-23 Trommsdorff Arzneimittel Ésteres de uridina farmaceuticamente activos
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
EP1800675B1 (en) * 2005-12-23 2011-05-18 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
WO2009002146A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
WO2010077292A1 (en) * 2008-12-09 2010-07-08 King Faisal Specialist Hospital & Research Center Pregnenolone sulfate for the treatment of neurologic disorders
WO2012091542A1 (en) * 2010-12-28 2012-07-05 N.V. Nutricia Combination of components for the prevention and treatment of frailty
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013129914A1 (en) * 2012-03-02 2013-09-06 N.V. Nutricia Method for improving functional synaptic connectivity
US20150044138A1 (en) * 2012-03-02 2015-02-12 N.V. Nutricia Method for improving functional synaptic connectivity
WO2013149384A1 (en) * 2012-04-05 2013-10-10 Nippon Suisan Kaisha, Ltd. Brain atrophy prevention agent
EP2906596B1 (en) * 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014171813A1 (en) * 2013-04-17 2014-10-23 N.V. Nutricia Nutritional composition for improving brain function in phenylketonuria
GB201405033D0 (en) * 2014-03-20 2014-05-07 Isis Innovation Combination therapy
RU2705208C2 (ru) * 2014-04-14 2019-11-06 Н.В. Нютрисиа Способ для оценки и лечения или профилактики нарушенных уровней полярных липидов в плазме

Also Published As

Publication number Publication date
PT3426237T (pt) 2023-11-17
US20190076375A1 (en) 2019-03-14
SI3426237T1 (sl) 2023-12-29
AU2017231577A1 (en) 2018-10-25
JP6980678B2 (ja) 2021-12-15
WO2017155396A1 (en) 2017-09-14
ES2962361T3 (es) 2024-03-18
CN109069447A (zh) 2018-12-21
AU2017231577B2 (en) 2022-04-07
EP3426237B1 (en) 2023-08-23
BR112018068110A2 (pt) 2019-01-15
HRP20231115T1 (hr) 2023-12-22
WO2017155386A1 (en) 2017-09-14
EP3426237A1 (en) 2019-01-16
EP3973956A1 (en) 2022-03-30
FI3426237T3 (fi) 2023-10-02
JP2019512488A (ja) 2019-05-16

Similar Documents

Publication Publication Date Title
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
ZA201706616B (en) Method for treating cancer
EP3426612B8 (en) Method for treating waste
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
IL257691A (en) A method for treating cancer
ZA202001141B (en) Zeolite after treatment method
GB2567616B (en) Treatment method
IL258988A (en) Methods for treating epilepsy
GB2571601B (en) Treatment method
SG11202001806TA (en) Treatment method
PL2913284T3 (pl) Sposób oraz urządzenie do obróbki części
PL3638630T3 (pl) Sposób obróbki szlamu
SI3426237T1 (sl) Postopek za zdravljenje možganske atrofije
SG10201508795XA (en) Method for treating cancer
IL258506A (en) A method for treating multiple sclerosis
ZA201903463B (en) Method for preparing hexadecahydropyrene
IL258878A (en) Method of adjustment
EP3383500A4 (en) METHOD OF TREATING HAIR
SG11201709067TA (en) Removal method for earth-retaining member
EP3421621B8 (en) Method for heat treating components
EP3246432A4 (en) Method for treating parts
GB201507268D0 (en) Method for stimulating aerogenosis
GB201503621D0 (en) Method for x-ray contrast enhancement